3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow Chronic Inflammatory Demyelinating Polyneuropathy: new trials by email Literature Review of Chronic Inflammatory Demyelinating Polyneuropathy trials Research Report on Chronic Inflammatory Demyelinating Polyneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Rituximab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | University of Kansas Medical Center | 2025-07-01 | 2025-09-17 | |
| Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy H.P. Acthar® Gel - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | Mamatha Pasnoor, MD | 2015-08-01 | 2016-07-18 | |
| High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | Stony Brook University | 2003-10-01 | 2021-11-09 |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3)
Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3) · Chronic Disease (3) · Demyelinating Diseases (3) · Disease Attributes (3) · Immune System Diseases (3) · Nervous System Diseases (3) · Neuromuscular Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Peripheral Nervous System Diseases (3) · Polyneuropathies (3) · Polyradiculoneuropathy (3)
Cyclophosphamide (1) · Rituximab (1)
Mamatha Pasnoor, MD (1) · Stony Brook University (1) · University of Kansas Medical Center (1)
United States (1)
Mamatha Pasnoor, MD (1) · Mazen Dimachkie, MD (1)